Abstract
Original language | English |
---|---|
Pages (from-to) | 1601-1612 |
Number of pages | 12 |
Journal | Ann. Oncol. |
Volume | 30 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- cancer
- chemotherapy
- cognitive
- gynecologic
- offspring
- pregnancy
- anthracycline
- bleomycin
- carboplatin
- cisplatin
- etoposide
- paclitaxel
- breast feeding
- cancer chemotherapy
- cancer hormone therapy
- cancer prognosis
- cancer registry
- cancer surgery
- cesarean section
- child care
- clinical protocol
- consensus
- diagnostic imaging
- drug targeting
- female genital tract cancer
- fetus development
- follow up
- gestational age
- health care personnel
- human
- hysterectomy
- long term care
- maternal care
- medical expert
- medical society
- multidisciplinary team
- newborn care
- ovary cancer
- practice guideline
- priority journal
- psychological aspect
- psychotherapy
- Review
- treatment planning
- uterine cervix cancer
- vaginal delivery
- vulva cancer
Fingerprint
Dive into the research topics of 'Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting: Annals of Oncology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting : Annals of Oncology. / Amant, F.; Berveiller, P.; Boere, I.A. et al.
In: Ann. Oncol., Vol. 30, No. 10, 2019, p. 1601-1612.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Gynecologic cancers in pregnancy: Guidelines based on a third international consensus meeting
T2 - Annals of Oncology
AU - Amant, F.
AU - Berveiller, P.
AU - Boere, I.A.
AU - Cardonick, E.
AU - Fruscio, R.
AU - Fumagalli, M.
AU - Halaska, M.J.
AU - Hasenburg, A.
AU - Johansson, A.L.V.
AU - Lambertini, M.
AU - Lok, C.A.R.
AU - Maggen, C.
AU - Morice, P.
AU - Peccatori, F.
AU - Poortmans, P.
AU - Van Calsteren, K.
AU - Vandenbroucke, T.
AU - Van Gerwen, M.
AU - Van Den Heuvel-Eibrink, M.
AU - Zagouri, F.
AU - Zapardiel, I.
N1 - Cited By :2 Export Date: 25 February 2020 CODEN: ANONE Correspondence Address: Amant, F.; Department of Oncology, KU Leuven, University of Leuven, Herestraat 49, Belgium; email: Frederic.amant@uzleuven.be Chemicals/CAS: bleomycin, 11056-06-7, 9041-93-4; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; etoposide, 33419-42-0, 433304-61-1; paclitaxel, 33069-62-4 Funding details: Fondazione IRCCS Policlinico San Matteo Funding details: KU Leuven Funding details: National and Kapodistrian University of Athens Funding details: Univerzita Karlova v Praze, UK Funding details: Karolinska Institutet, KI Funding details: European SocieTy for Radiotherapy and Oncology, ESTRO Funding text 1: 1Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute/Antoni van Leeuwenhoek and Amsterdam University Medical Centers, the Netherlands; 2Department of Oncology, KU Leuven, Leuven, Belgium; 3Department of Obstetrics and Gynecology, Centre Hospitalier de Poissy-Saint-Germain-en-Laye, Poissy, France; 4Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; 5Department of Obstetrics and Gynecology, Cooper University Health Care, Camden, USA; 6Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza; 7Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Neonatal Intensive Care Unit, Milan; 8Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; 9Department of Obstetrics and Gynaecology, 3rd Medical Faculty, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic; 10Department of Obstetrics and Gynecology, Mainz University Medical Center, Mainz, Germany; 11Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 12Department of Medical Oncology, IRCCS Policlinico San Martino Hospital, Genova; 13Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; 14Department of Gynecologic Surgery, Institute de Cancérologie Gustave Roussy, Villejuif, France; 15Department of Gynecologic Oncology, European Institute of Oncology IRCCS, Milan, Italy; 16Department of Radiation Oncology, Institut Curie and Paris Sciences & Lettres - PSL University, Paris, France; 17Department of Development and Regeneration, University Hospitals Leuven, Leuven, Belgium; 18Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; 19Department of Clinical Therapeutics, Alexandra Hospital, Medical School, University of Athens, Athens, Greece; 20Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain *Correspondence to: Prof. Frédéric Amant, Department of Oncology, KU Leuven - University of Leuven, Herestraat 49, Leuven 3000, Belgium. Tel: +32-16344273; E-mail: Frederic.amant@uzleuven.be Funding text 2: This consensus meeting was sponsored by European Society of Gynaecological Oncology (ESGO) [no grant number applies]. References: Amant, F., Van Calsteren, K., Halaska, M.J., Gynecologic cancers in pregnancy (2009) J Gynecol Cancer, 19, pp. S1-S12; Amant, F., Halaska, M.J., Fumagalli, M., Gynecologic cancers in pregnancy: Guidelines of a second international consensus meeting (2014) J Gynecol Cancer, 24 (3), pp. 394-403; Eibye, S., Kjær, S.K., Mellemkjær, L., Incidence of pregnancy-associated cancer in Denmark, 1977-2006 (2013) Obstet Gynecol, 122 (3), pp. 608-617; Lee, Y.Y., Roberts, C.L., Dobbins, T., Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: A population-based linkage study (2012) BJOG, 119 (13), pp. 1572-1582; Smith, L.H., Danielsen, B., Allen, M.E., Cress, R., Cancer associated with obstetric delivery: Results of linkage with the California cancer registry (2003) Am J Obstet Gynecol, 189 (4), pp. 1128-1135; Amant, F., Verheecke, M., Wlodarska, I., Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing (2015) JAMA Oncol, 1 (6), pp. 814-819; Cottreau, C.M., Dashevsky, I., Andrade, S.E., Pregnancy-associated cancer: A U.S population-based study (2019) J Womens Health (Larchmt), 28 (2), pp. 250-257; Parazzini, F., Franchi, M., Tavani, A., Frequency of pregnancy related cancer: A population based linkage study in Lombardy, Italy (2017) J Gynecol Cancer, 27 (3), pp. 613-619; Andersson, T.-L., Johansson, A.V., Fredriksson, I., Lambe, M., Cancer during pregnancy and the postpartum period: A population-based study (2015) Cancer, 121 (12), pp. 2072-2077; Dalrymple, J.L., Gilbert, W.M., Leiserowitz, G.S., Pregnancy-associated cervical cancer: Obstetric outcomes (2005) J Matern Fetal Neonatal Med, 17 (4), pp. 269-276; Nazer, A., Czuzoj-Shulman, N., Oddy, L., Abenhaim, H.A., Incidence of maternal and neonatal outcomes in pregnancies complicated by ovarian masses (2015) Arch Gynecol Obstet, 292 (5), pp. 1069-1074; Leiserowitz, G.S., Xing, G., Cress, R., Adnexal masses in pregnancy: How often are they malignant (2006) Gynecol Oncol, 101 (2), pp. 315-321; Stensheim, H., Møller, B., Van Dijk, T., Fossa, S.D., Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: A registrybased cohort study (2009) J Clin Oncol, 27 (1), pp. 45-51; Halaska, M.J., Uzan, C., Han, S.N., Characteristics of patients with cervical cancer during pregnancy: A multicenter matched cohort study An initiative from the International Network on Cancer, Infertility and Pregnancy (2019) J Gynecol Cancer, 29 (4), p. 676; Yael, H.K., Lorenza, P., Evelina, S., Incidental endometrial adenocarcinoma in early pregnancy (2009) J Gynecol Cancer, 19 (9), pp. 1580-1584; Haas, J.F., Pregnancy in association with a newly diagnosed cancer: A population-based epidemiologic assessment (1984) J Cancer, 34 (2), pp. 229-235; Matsuo, K., Whitman, S.A., Blake, E.A., Feto-maternal outcome of pregnancy complicated by vulvar cancer: A systematic review of literature (2014) Eur J Obstet Gynecol Reprod Biol, 179, pp. 216-223; Soo-Hoo, S., Luesley, D., Vulval and vaginal cancer in pregnancy (2016) Best Pract Res Clin Obstet Gynaecol, 33, pp. 73-78; Hasanzadeh, M., Zamiri-Akhlaghi, A., Hassanpoor-Moghaddam, M., Shahidsales, S., Vulvar carcinoma in pregnant women aged less than 40 years: Case report (2014) Iran J Cancer Prev, 7, pp. 175-178; Lecointre, L., Gaudineau, A., Hild, C., Carcinome epidermoïde de la vulve et grossesse: Des choix difficiles (2015) Gynecologie Obs Fertil, 43 (9), pp. 625-627; Fujita, K., Aoki, Y., Tanaka, K., Stage i squamous cell carcinoma of vagina complicating pregnancy: Successful conservative treatment (2005) Gynecol Oncol, 98 (3), pp. 513-515; Akil, A., Kaya, B., Karabay, A., Kibar, Y., Concurrent endometrial adenocarcinoma and an early pregnancy loss (2012) Arch Gynecol Obstet, 286 (4), pp. 1089-1090; Zhou, F., Qian, Z., Li, Y., Endometrial adenocarcinoma in spontaneous abortion: Two cases and review of the literature (2015) J Clin Exp Med, 8, pp. 8230-8233; Valentin, J., Biological effects after prenatal irradiation (embryo and fetus) (2003) Ann ICRP, 33, pp. 1-206; De Haan, J., Verheecke, M., Van Calsteren, K., Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: A 20-year international cohort study of 1170 patients (2018) Lancet Oncol, 19 (3), pp. 337-346; Ray, J.G., Vermeulen, M.J., Bharatha, A., Association between MRI exposure during pregnancy and fetal and childhood outcomes (2016) JAMA, 316 (9), p. 952; Papadia, A., Mohr, S., Imboden, S., Laparoscopic indocyanine green sentinel lymph node mapping in pregnant cervical cancer patients (2016) J Minim Invasive Gynecol, 23 (2), pp. 270-273; Han, S.N., Amant, F., Michielsen, K., Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: A pilot study (2018) Eur Radiol, 28 (5), pp. 1862-1874; Peccatori, F.A., Codacci-Pisanelli, G., Del Grande, M., Whole body MRI for systemic staging of breast cancer in pregnant women (2017) Breast, 35, pp. 177-181; Frisch, A., Walter, T.C., Hamm, B., Denecke, T., Efficacy of oral contrast agents for upper gastrointestinal signal suppression in MRCP: A systematic review of the literature (2017) Acta Radiol Open, 6 (9). , 2058460117727315; Mazze, R.I., Kallen, B., Reproductive outcome after anesthesia and operation during pregnancy: A registry study of 5405 cases (1989) Am J Obstet Gynecol, 161 (5), pp. 1178-1185; Lee, A.J., Landau, R., Mattingly, J.L., Left lateral table tilt for elective cesarean delivery under spinal anesthesia has no effect on neonatal acid-base status (2017) Anesthesiology, 127 (2), pp. 241-249; Shigemi, D., Aso, S., Matsui, H., Safety of laparoscopic surgery for benign diseases during pregnancy: A nationwide retrospective cohort study (2019) J Minim Invasive Gynecol, 26 (3), pp. 501-506; Webb, K., Sakhel, K., Chauhan, S., Abuhamad, A., Adnexal mass during pregnancy: A review (2015) Am J Perinatol, 32 (11), pp. 1010-1016; Estadella, J., Espa~nol, P., Grandal, B., Laparoscopy during pregnancy: Case report and key points to improve laparoscopic management (2017) Eur J Obstet Gynecol Reprod Biol, 217, pp. 83-88; Jackson, H., Granger, S., Price, R., Diagnosis and laparoscopic treatment of surgical diseases during pregnancy: An evidence-based review (2008) Surg Endosc, 22 (9), pp. 1917-1927; Ye, P., Zhao, N., Shu, J., Laparoscopy versus open surgery for adnexal masses in pregnancy: A meta-analytic review (2019) Arch Gynecol Obstet, 299 (3), pp. 625-634; Evans, S.R.T., Sarani, B., Bhanot, P., Feldman, E., Surgery in pregnancy (2012) Curr Probl Surg, 49 (6), pp. 333-388; Bhatla, N., Aoki, D., Sharma, D.N., Sankaranarayanan, R., Cancer of the cervix uteri (2018) J Gynaecol Obstet, 143, pp. 22-36; Covens, A., Rosen, B., Murphy, J., How important is removal of the parametrium at surgery for carcinoma of the cervix (2002) 4 Gynecol Oncol, 84 (1), pp. 145-149; Strnad, P., Robova, H., Skapa, P., A prospective study of sentinel lymph node status and parametrial involvement in patients with small tumour volume cervical cancer (2008) Gynecol Oncol, 109 (2), pp. 280-284; Morice, P., Uzan, C., Gouy, S., Gynaecological cancers in pregnancy (2012) Lancet, 379 (9815), pp. 558-569; Rydzewska, L., Tierney, J., Vale, C.L., Symonds, P.R., Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer (2012) Cochrane Database Syst Rev, 12, p. CD007406; Cibula, D., Potter, R., Planchamp, F., The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer (2018) J Gynecol Cancer, 28 (4), pp. 641-655; Sood, A.K., Sorosky, J.I., Mayr, N., Radiotherapeutic management of cervical carcinoma that complicates pregnancy (1997) Cancer, 80 (6), pp. 1073-1078; Van Maaren, M.C., Bretveld, R.W., Jobsen, J.J., The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival (2017) Br J Cancer, 117 (2), pp. 179-188; Weisz, B., Meirow, D., Schiff, E., Lishner, M., Impact and treatment of cancer during pregnancy (2004) Expert Rev Anticancer Ther, 4 (5), pp. 889-902; Sood, A.K., Shahin, M.S., Sorosky, J.I., Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy (2001) Gynecol Oncol, 83 (3), pp. 599-600; Ngu, S.-F., Ngan, H., Chemotherapy in pregnancy (2016) Best Pract Res Clin Obstet Gynaecol, 33, pp. 86-101; Cardonick, E., Iacobucci, A., Use of chemotherapy during human pregnancy (2004) Lancet Oncol, 5 (5), pp. 283-291; Shachar, S.S., Gallagher, K., McGuire, K., Multidisciplinary management of breast cancer during pregnancy (2017) Oncologist, 22 (3), pp. 324-334; Ricci, C., Scambia, G., De Vincenzo, R., Locally advanced cervical cancer in pregnancy (2016) J Gynecol Cancer, 26 (8), pp. 1490-1496; Mir, O., Berveiller, P., Goffinet, F., Taxanes for breast cancer during pregnancy: A systematic review (2010) Ann Oncol, 21 (2), pp. 425-426; Zheng, X., Zhu, Y., Zhao, Y., Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review (2017) J Clin Pharmacol Ther, 55, pp. 753-760; Robova, H., Halaska, M.J., Pluta, M., Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertilitysparing surgery in cervical cancer (2014) Gynecol Oncol, 135 (2), pp. 213-216; Sadler, N.C., Nandhikonda, P., Webb-Robertson, B.-J., Hepatic cytochrome P450 activity, abundance, and expression throughout human development (2016) Drug Metab Dispos, 44 (7), pp. 984-991; Amant, F., Vandenbroucke, T., Verheecke, M., Pediatric outcome after maternal cancer diagnosed during pregnancy (2015) N Engl J Med, 373 (19), pp. 1824-1834; Geijteman, E.C.T., Wensveen, C.W.M., Duvekot, J.J., Van Zuylen, L., A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy (2014) Obstet Gynecol, 124, pp. 454-456; Raffles, A., Williams, J., Costeloe, K., Clark, P., Transplacental effects of maternal cancer chemotherapy (1989) Case Report. Br J Obstet Gynaecol, 96 (9), pp. 1099-1100; Han, J.-Y., Nava-Ocampo, A.A., Kim, T.-J., Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: Report of 2 cases (2005) Reprod Toxicol, 19 (4), pp. 557-561; Cardonick, E., Usmani, A., Ghaffar, S., Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy (2009) Am J Clin Oncol, 33, p. 1; Ghaemmaghami, F., Abbasi, F., Abadi, A., A favorable maternal and neonatal outcome following chemotherapy with etoposide, bleomycin, and cisplatin for management of grade 3 immature teratoma of the ovary (2009) J Gynecol Oncol, 20 (4), pp. 257-259; Pregnancy and medical radiation (2000) Ann ICRP, 84, pp. 1-43; Kal, H.B., Struikmans, H., Radiotherapy during pregnancy: Fact and fiction (2005) Lancet Oncol, 6 (5), pp. 328-333; Vandenbroucke, T., Verheecke, M., Fumagalli, M., Effects of cancer treatment during pregnancy on fetal and child development (2017) Lancet Child Adolesc Heal, 1 (4), pp. 302-310; Kyrgiou, M., Athanasiou, A., Paraskevaidi, M., Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: Systematic review and meta-analysis (2016) BMJ, 354, p. i3633; Choi, S.-J., Use of progesterone supplement therapy for prevention of preterm birth: Review of literatures (2017) Obstet Gynecol Sci, 60 (5), pp. 405-420; Halaska, M.J., Komar, M., Vlk, R., A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy (2014) Eur J Obstet Gynecol Reprod Biol, 174, pp. 76-79; Manuel-Limson, G.A., Ladines-Llave, C.A., Sotto, L.S., Manalo, A.M., Cancer of the cervix in pregnancy: A 31-year experience at the philippine general hospital (1997) J Obstet Gynaecol Res, 23 (6), pp. 503-509; Nisker, J.A., Shubat, M., Stage IB cervical carcinoma and pregnancy: Report of 49 cases (1983) Am J Obstet Gynecol, 145 (2), pp. 203-206; Vandervange, N., Weverling, G., Ketting, B., The prognosis of cervical cancer associated with pregnancy: A matched cohort study (1995) Obstet Gynecol, 85 (6), p. 1022; Tewari, K., Cappuccini, F., Gambino, A., Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: A report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapy (1998) Cancer, 82 (8), pp. 1529-1534; Bigelow, C.A., Horowitz, N.S., Goodman, A., Management and outcome of cervical cancer diagnosed in pregnancy (2017) Am J Obstet Gynecol, 216 (3), pp. 276e1-276e6; Hase, E., Barros, V., Igai, A., Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score (2018) Clinics, 73, p. e368; Han, S.N., Van Peer, S., Peccatori, F., Contraception is as important as fertility preservation in young women with cancer (2015) Lancet, 385 (9967), p. 508; Stopenski, S., Aslam, A., Zhang, X., Cardonick, E., After chemotherapy treatment for maternal cancer during pregnancy, is breastfeeding possible (2017) Breastfeed Med, 12 (2), pp. 91-97; Can, N.T.T., Robertson, P., Zaloudek, C.J., Gill, R.M., Cervical squamous cell carcinoma metastatic to placenta (2013) J Gynecol Pathol, 32 (5), pp. 516-519; Cailliez, D., Moirot, M.H., Fessard, C., Placental localisation of cancer of the cervix (author's transl) (1980) J Gynecol Obstet Biol Reprod (Paris), 9, pp. 461-463; Frick, R., Rummel, H., Heberling, D., Schmidt, W.O., Placental metastases from a maternal angioblastic sarcoma of the vagina (author's transl) (1977) Geburtshilfe Frauenheilkd, 37, pp. 216-220; Alexander, A., Samlowski, W.E., Grossman, D., Metastatic melanoma in pregnancy: Risk of transplacental metastases in the infant (2003) J Clin Oncol, 21 (11), pp. 2179-2186; Orr, J.W., Grizzle, W.E., Huddleston, J.F., Squamous cell carcinoma metastatic to placenta and ovary (1982) Obstet Gynecol, 59, pp. 81S-83S; Greaves, M., Hughes, W., Cancer cell transmission via the placenta (2018) Evol Med Public Health, 2018 (1), pp. 106-115; Clemens, E., De Vries, A.C., Pluijm, S.F., Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study (2016) Eur J Cancer, 69, pp. 77-85; Clemens, E., De Vries, A.C., Zehnhoff-Dinnesen, A., Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors (2017) Pediatr Hematol Oncol, 34 (2), pp. 120-129; Mennes, M., Stiers, P., Vandenbussche, E., Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only (2005) Pediatr Blood Cancer, 44, pp. 478-486; Van Der Plas, E., Erdman, L., Nieman, B.J., Characterizing neurocognitive late effects in childhood leukemia survivors using a combination of neuropsychological and cognitive neuroscience measures (2018) Child Neuropsychol, 24 (8), pp. 999-1014; Travis, L.B., Fossa, S.D., Sesso, H.D., Chemotherapy-induced peripheral neurotoxicity and ototoxicity: New paradigms for translational genomics (2014) JNCI J Natl Cancer Inst, 106 (5), p. dju044; Peleva, E., Emami, N., Alzahrani, M., Incidence of platinum-induced ototoxicity in pediatric patients in Quebec (2014) Pediatr Blood Cancer, 61 (11), pp. 2012-2017; Kremer, L.C.M., Mulder, R.L., Oeffinger, K.C., A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group (2013) Pediatr Blood Cancer, 60 (4), pp. 543-549; Amant, F., Van Calsteren, K., Halaska, M.J., Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study (2012) Lancet Oncol, 13 (3), pp. 256-264; Cardonick, E.H., Gringlas, M.B., Hunter, K., Greenspan, J., Development of children born to mothers with cancer during pregnancy: Comparing in utero chemotherapy-exposed children with nonexposed controls (2015) Am J Obstet Gynecol, 212 (5), pp. 658e1-658e8; Aviles, A., Neri, N., Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero (2001) Clin Lymphoma, 2 (3), pp. 173-177; Aviles, A., Neri, N., Nambo, M.-J., Hematological malignancies and pregnancy: Treat or no treat during first trimester (2012) J Cancer, 131 (11), pp. 2678-2683; Aviles, A., Neri, N., Nambo, M.J., Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy (2006) Ann Oncol, 17 (2), pp. 286-288; Yancey, A., Harris, M.S., Egbelakin, A., Risk factors for cisplatinassociated ototoxicity in pediatric oncology patients (2012) Pediatr Blood Cancer, 59 (1), pp. 144-148; Mulder, E.J.H., De Medina, P.G., Huizink, A.C., Prenatal maternal stress: Effects on pregnancy and the (unborn) child (2002) Early Hum Dev, 70 (1-2), pp. 3-14; Loomans, E.M., Van Dijk, A.E., Vrijkotte, T.G.M., Psychosocial stress during pregnancy is related to adverse birth outcomes: Results from a large multi-ethnic community-based birth cohort (2013) Eur J Public Health, 23 (3), pp. 485-491; Vomvolaki, E., Kalmantis, K., Kioses, E., Antsaklis, A., The effect of hysterectomy on sexuality and psychological changes (2006) Eur J Contracept Reprod Health Care, 11 (1), pp. 23-27; Vandenbroucke, T., Han, S.N., Van Calsteren, K., Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners (2017) Psychooncology, 26 (8), pp. 1215-1221
PY - 2019
Y1 - 2019
N2 - We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
AB - We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
KW - cancer
KW - chemotherapy
KW - cognitive
KW - gynecologic
KW - offspring
KW - pregnancy
KW - anthracycline
KW - bleomycin
KW - carboplatin
KW - cisplatin
KW - etoposide
KW - paclitaxel
KW - breast feeding
KW - cancer chemotherapy
KW - cancer hormone therapy
KW - cancer prognosis
KW - cancer registry
KW - cancer surgery
KW - cesarean section
KW - child care
KW - clinical protocol
KW - consensus
KW - diagnostic imaging
KW - drug targeting
KW - female genital tract cancer
KW - fetus development
KW - follow up
KW - gestational age
KW - health care personnel
KW - human
KW - hysterectomy
KW - long term care
KW - maternal care
KW - medical expert
KW - medical society
KW - multidisciplinary team
KW - newborn care
KW - ovary cancer
KW - practice guideline
KW - priority journal
KW - psychological aspect
KW - psychotherapy
KW - Review
KW - treatment planning
KW - uterine cervix cancer
KW - vaginal delivery
KW - vulva cancer
U2 - 10.1093/annonc/mdz228
DO - 10.1093/annonc/mdz228
M3 - Article
VL - 30
SP - 1601
EP - 1612
JO - Ann. Oncol.
JF - Ann. Oncol.
SN - 1569-8041
IS - 10
ER -